Theranostic Nanoparticles in Prostate Cancer: Disrupting Hypoxia‐Induced Glycolysis by Targeting Hypoxia‐Inducible Factor‐1 Alpha and Downstream Metabolites

TNPs are a promising platform to integrate diagnosis and treatment of PCa as they incorporate features of targeted delivery, on-line monitoring and interference with HIF-1a regulated glycolysis. Future advances will require interdisciplinary optimization, development of better tumor-targeting approaches, and artificial intelligence guided nanoparticle design to facilitate clinical scale up and regulation of technically and clinically acceptable theranostics of nanomedicines for PCa.